Day: April 1, 2026

Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year

Written by Customer Service on April 1, 2026. Posted in Earnings Releases And Operating Results.

International Cannabis Accelerates with 73% Net Revenue Growth and 100% Increase in Cannabis Flower Sales Volume Year-Over-Year Canadian Adult-Use and Medical Cannabis Net Revenue Combined Increased 8% Year-Over-Year; Tilray Maintains #1 Cannabis Leadership Position in Canada by Revenue BrewDog Acquisition1 for ~£40 Million Cash Positions Tilray as a Global Craft Beverage Leader with Multi-Region Expansion Across Europe, Middle East, Australia, Asia-Pacific and the U.S. Strong Balance Sheet Supports Growth with $265 Million in Cash and Marketable Securities2 and ~$3.5 Million Net Cash NEW YORK and LONDON and LEAMINGTON, Ontario, April 01, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis,...

FitLife Brands Announces Fourth Quarter and Full-Year 2025 Results

Written by Customer Service on April 1, 2026. Posted in Earnings Releases And Operating Results.

OMAHA, NE, April 01, 2026 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the fourth quarter and full year ended December 31, 2025. Highlights for the fourth quarter ended December 31, 2025 include:Total revenue was $25.9 million, an increase of 73% compared to the fourth quarter of 2024. Wholesale revenue was $15.5 million, or 60% of total revenue, an increase of 213% compared to the fourth quarter of 2024. Online revenue was $10.5 million, or 40% of total revenue, an increase of 4% compared to the fourth quarter of 2024. Excluding the amortization of the inventory step-up related to the Irwin acquisition, gross margin was 37.0% compared to 41.4% during the fourth...

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

Written by Customer Service on April 1, 2026. Posted in Public Companies.

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) — NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company’s common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at an exercise price of $3.025 per share. The offering includes participation from...

MiniLuxe Announces Follow-On Investment of up to US$1.75M from Flow Capital

Written by Customer Service on April 1, 2026. Posted in Public Companies.

Company expands on its relationship with Flow Capital. Boston, MA, April 01, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX)(“MiniLuxe” or the “Company”), the pioneer in clean nail care and ethical nail services, is pleased to announce that Flow Capital Corporation (TSXV:FW) (“Flow Capital”), a leading provider of flexible growth capital and alternative debt solutions, has completed a follow-on investment of up to US$1.75M pursuant to its existing term loan with the Company, bringing the total amount available to the Company under the facility to up to US$7.925 million. Under the new tranche of the loan, an initial advance of US$1.35 million was funded to the Company on closing, and the Company is also eligible to receive an additional advance of up to US$400,000, subject to the satisfaction of certain financing milestones,...

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Written by Customer Service on April 1, 2026. Posted in Public Companies.

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathiesMALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies). “This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative...

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Written by Customer Service on April 1, 2026. Posted in Public Companies.

Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or life-threatening condition MIAMI, April 01, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. “We appreciate the FDA’s decision that PAS-004 meets the criteria for Fast Track designation for this indication,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “The ability...

Whitestone REIT Adds Premier Tenant at BLVD Place, Signs Agreement for Parkhill’s Houston Headquarters

Written by Customer Service on April 1, 2026. Posted in Public Companies.

Multidisciplinary architecture and engineering firm to occupy approximately 5,800 square feet at the mixed-use center HOUSTON, April 01, 2026 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced it has signed an approximately 5,800-square-foot lease with Parkhill, a multidisciplinary architecture and engineering firm, to open a new office presence in Houston at BLVD Place located in the prestigious Uptown District. The agreement highlights the type of high-credit-quality tenants that are being drawn to the mixed-use center because of its prime location and amenities. Parkhill’s second-floor workspace at BLVD Place epitomizes the type of dynamic setting that is critical for employee retention and attracting the next generation...

Amaze Reports Full Year 2025 Financial Results and Strategic Transformation

Written by Customer Service on April 1, 2026. Posted in Earnings Releases And Operating Results.

2025 Marked a Year of Consolidation, Platform Integration, and Strategic Foundation for Commerce-Led Growth in 2026 NEWPORT BEACH, Calif., April 01, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a creator-powered commerce platform enabling creators and brands to sell products globally, today reported financial results for the full year ended December 31, 2025. Management Commentary “2025 was a foundational year for Amaze,” said Aaron Day, Chief Executive Officer of Amaze. “Following the acquisition of Amaze Software and our transition from Fresh Vine into a creator-powered social commerce platform, we spent 2025 consolidating operations, strengthening our technology stack, reducing costs, and positioning the business for scalable growth.” During the year, the Company began development...

Man Group PLC : Form 8.3 – A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited

Written by Customer Service on April 1, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date...

LVMH: AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENT

Written by Customer Service on April 1, 2026. Posted in Public Companies.

Paris, April 1st, 2026 LVMH Moët Hennessy Louis Vuitton announces the availability of its 2025 Universal Registration Document (URD), in accordance with applicable regulations. The French version of this document was filed with the “Autorité des marchés financiers” (AMF) on March 31st, 2026 in ESEF format (European Single Electronic Format) under the reference D.26-0195. The English translation of this document may be consulted on the Company’s website www.lvmh.com (under Investors / Investors and Analysts / Publications). It is equally available on the AMF website: www.amf-france.org. This document includes in particular: – the 2025 annual financial report;– the Board of Directors’ management report, to which are attached the Board of Directors’ report on corporate governance and the sustainability report;– the Statutory...

Day: April 1, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals